Learn about Fetroja, a cephalosporin antibacterial for the treatment of cUTI and HABP/VABP infections caused by certain susceptible Gram-negative microorganisms. Please see Important Safety Information and Full Prescribing Information on this website.

Cefiderocol, sold under the brand name Fetroja (by Shionogi) among others, is an antibiotic used to treat complicated urinary tract infections when no other options are available. [5] It is indicated for the treatment of multi-drug-resistant Gram-negative bacteria including Pseudomonas aeruginosa. [6][7][8] It is given by injection into a vein. [1]

2020年9月，日本药企盐野义（Shionogi）宣布，美国食品和药物管理局（FDA）已批准新型抗菌药Fetroja（cefiderocol，头孢地尔）的一份补充新药申请（sNDA），用于18岁及以上成人患者，治疗由下列易感革兰氏阴性菌引…

FETROJA® is indicated in patients 18 years of age or older for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis caused by the following susceptible...

2024年12月20日 · 2020年9月，日本药企盐野义（Shionogi）宣布，美国食品和药物管理局（FDA）已批准新型抗菌药Fetroja（cefiderocol，头孢地尔）的一份补充新药申请（sNDA），用于18岁及以上成人患者，治疗由下列易感革兰氏阴性菌引起的医院获得性细菌性肺炎（HABP）和 …

Fetroja ® (cefiderocol) is indicated in patients 18 years of age or older for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis caused by the following susceptible Gram-negative microorganisms: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Enterobacter cloacae complex.

FETROJA®（cefiderocol）是首个获批的铁载体头孢菌素抗菌药物。 Cefiderocol以Fetcroja（由 Shionogi 公司生产）等品牌出售，是一种用于治疗复杂性 尿路感染（在没有其他选择时）的抗生素。

FETROJA is used to treat adults who have a complicated urinary tract infection (abbreviated as cUTI) including infection of the kidneys (pyelonephritis) caused by specific bacteria. It should be...

cefiderocol首个被批准的具有铁 载体 功能的 抗生素，于2019年11月14日在美国获批（Fetroja）、2020年4月在欧盟获批（Fetcroja），用于治疗选择有限或没有治疗选择的18岁及以上成人患者，治疗由易感革兰氏阴性菌导致的感染。 cefiderocol是一种新型铁 载体 头孢菌素，具有独特的穿透革兰氏阴性菌（包括多药耐药菌）细胞膜的作用机制，具有克服碳青霉烯耐药3种主要机制（孔蛋白通道改变、β-内酰胺酶失活、外排泵过量产生）的独特能力。 cefiderocol与三价铁结合， …

FETROJA® is indicated in patients 18 years of age or older for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis caused by the following susceptible Gram-negative microorganisms: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Enterobacter cloacae complex [see ...